icon_folder.gif   Conference Reports for NATAP  
American Association For The Study of Liver Diseases
November 11-15, 2005 San Francisco
Back grey_arrow_rt.gif
Pradefovir, New HBV Drug: 24 Wks
  Reported by Jules Levin
AASLD, Nov 2005, San Francisco
"Safety, Tolerability, Antiviral Activity and Pharmacokinetics of Pradefovir Mesylate in Patients with Chronic Hepatitis B Virus Infection: 24-Week Interim Analysis of a Phase II Study"
Seng Gee Lim; Kwan Sik Lee;
Wan-Long Chuang; Seong Gyu Hwang;
Mong Cho; Ming-Yang Lai; You-Chen Chao;
Ting-Tsung Chang; Yi Xu; John Sullivan-Bolyai;
Valeant Pharmaceuticals International Pradefovir Phase II Study Group



- A liver-targeting & kidney-sparing prodrug
- Safer than or as safe as ADV in animal toxicology studies
- Rapid absorption and conversion in human
- No food effect nor gender effect
- Neither an inhibitor nor an inducer of CYP3A4
- Excellent dose proportionality
- Potent anti-HBV activity observed
- Well tolerated at all doses tested